(Reuters) — James Ward-Lilley, the former AstraZeneca executive who created a UK respiratory medicine business in June by merging Vectura and SkyePharma, is already thinking about his next deal.
This time he’d like to buy a company with an established U.S. sales force to accelerate the group’s ambitions as it develops specialized lung drugs that are wholly owned by Vectura, rather than partnered with Big Pharma.
Get the full story at our sister site, Drug Delivery Business News.
The post Vectura on the hunt for specialized lung drug business appeared first on MassDevice.